Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat in thalassemia and sickle cell disease
NCT04987489Phase 2Completed
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Mar 2022
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of etavopivat in thalassemia, sickle cell disease (SCD), sponsored by Forma Therapeutics, Inc.. Started Mar 2022; status: completed.
02
Drugs
etavopivat
03
Conditions
thalassemiasickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04987489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987489.